Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2024-11-11 Sale |
2024-11-12 7:20 pm |
Aurinia Pharmaceuticals Inc. | AUPH | Smith Karen L. Director |
5,241 | $8.43 | $44,182 | 12,672 (Direct) |
View |
| 2022-05-24 Sale |
2022-05-26 5:26 pm |
ANTARES PHARMA INC. | ATRS | Smith Karen L. Director |
79,645 | $5.6 | $446,012 | 0 (Direct) |
View |
| 2021-04-05 Sale |
2021-04-05 8:17 pm |
ACCELERON PHARMA INC | XLRN | Smith Karen L. Director |
11,864 | $140.19 | $1,663,156 | 19,457 (Direct) |
View |
| 2021-04-01 Sale |
2021-04-02 6:00 pm |
ACCELERON PHARMA INC | XLRN | Smith Karen L. Director |
8,925 | $136.47 | $1,218,003 | 31,321 (Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2025-02-24 Option Award |
2025-02-26 5:45 pm |
N/A 2035-02-25 |
Skye Bioscience Inc. | SKYE | Smith Karen L. Director |
35,000 | $0 | 35,000 (Direct) |
View |
| 2024-11-21 Option Award |
2024-11-25 4:38 pm |
N/A 2034-11-21 |
Aurinia Pharmaceuticals Inc. | AUPH | Smith Karen L. Director |
30,776 | $0 | 43,448 (Direct) |
View |
| 2024-11-08 Exercise |
2024-11-12 7:20 pm |
N/A N/A |
Aurinia Pharmaceuticals Inc. | AUPH | Smith Karen L. Director |
17,913 | $0 | 12,672 (Direct) |
View |
| 2024-10-28 Option Award |
2024-10-30 8:28 pm |
N/A 2034-10-27 |
Skye Bioscience Inc. | SKYE | Smith Karen L. Director |
70,000 | $0 | 70,000 (Direct) |
View |
| 2024-09-04 Option Award |
2024-09-05 08:15 am |
N/A 2034-09-03 |
Context Therapeutics Inc. | CNTX | Smith Karen L. Director |
19,315 | $0 | 19,315 (Direct) |
View |
| 2024-07-02 Option Award |
2024-07-05 08:59 am |
N/A 2034-07-01 |
Skye Bioscience Inc. | SKYE | Smith Karen L. Director |
40,000 | $0 | 40,000 (Direct) |
View |
| 2024-06-04 Option Award |
2024-06-06 4:26 pm |
N/A 2034-06-03 |
SANGAMO THERAPEUTICS INC | SGMO | Smith Karen L. Director |
75,000 | $0 | 127,100 (Direct) |
View |
| 2023-08-18 Option Award |
2023-08-21 4:19 pm |
N/A N/A |
Aurinia Pharmaceuticals Inc. | AUPH | Smith Karen L. Director |
46,872 | $0 | 46,872 (Direct) |
View |
| 2023-06-13 Option Award |
2023-06-14 7:02 pm |
N/A 2033-06-13 |
Talaris Therapeutics Inc. | TALS | Smith Karen L. Director |
20,500 | $0 | 20,500 (Direct) |
View |
| 2023-06-01 Option Award |
2023-06-05 4:52 pm |
N/A 2033-05-31 |
SANGAMO THERAPEUTICS INC | SGMO | Smith Karen L. Director |
41,650 | $0 | 79,850 (Direct) |
View |
| 2023-02-01 Option Award |
2023-02-02 6:35 pm |
N/A 2033-01-31 |
Quince Therapeutics Inc. | QNCX | Smith Karen L. Chief Medical Officer |
225,000 | $0 | 225,000 (Direct) |
View |
| 2022-06-09 Option Award |
2022-06-13 6:16 pm |
N/A 2032-06-08 |
Talaris Therapeutics Inc. | TALS | Smith Karen L. Director |
14,501 | $0 | 14,501 (Direct) |
View |
| 2022-05-19 Option Award(A) |
2022-05-27 5:37 pm |
N/A N/A |
Cortexyme Inc. | CRTX | Smith Karen L. Chief Medical Officer |
170,354 | $0 | 194,690 (Direct) |
View |
| 2022-05-19 Option Award |
2022-05-23 8:24 pm |
N/A 2032-03-27 |
Cortexyme Inc. | CRTX | Smith Karen L. Chief Medical Officer |
1,541,584 | $0 | 1,541,584 (Direct) |
View |
| 2022-05-16 Option Award |
2022-05-17 6:15 pm |
N/A 2032-05-15 |
Talaris Therapeutics Inc. | TALS | Smith Karen L. Director |
29,002 | $0 | 29,002 (Direct) |
View |
| 2022-02-25 Option Award |
2022-03-01 5:14 pm |
N/A 2032-02-24 |
SANGAMO THERAPEUTICS INC | SGMO | Smith Karen L. Director |
37,500 | $0 | 63,200 (Direct) |
View |
| 2021-11-19 Equity Swap |
2021-11-22 09:09 am |
N/A N/A |
ACCELERON PHARMA INC | XLRN | Smith Karen L. Director |
1,622 | $0 | 0 (Direct) |
View |
| 2021-06-10 Option Award |
2021-06-14 6:27 pm |
N/A N/A |
ANTARES PHARMA INC. | ATRS | Smith Karen L. Director |
25,452 | $4.42 | 128,187 (Direct) |
View |
| 2021-06-10 Option Award |
2021-06-14 6:27 pm |
N/A 2031-06-10 |
ANTARES PHARMA INC. | ATRS | Smith Karen L. Director |
48,542 | $0 | 128,187 (Direct) |
View |
| 2021-05-07 Tax Withholding |
2021-05-11 4:30 pm |
N/A N/A |
Emergent BioSolutions Inc. | EBS | Smith Karen L. EVP, Chief Medical Officer |
305 | $60.85 | 11,888 (Direct) |
View |
| 2021-04-05 Exercise |
2021-04-05 8:17 pm |
N/A N/A |
ACCELERON PHARMA INC | XLRN | Smith Karen L. Director |
5,000 | $35.34 | 19,457 (Direct) |
View |
| 2021-04-05 Exercise |
2021-04-05 8:17 pm |
N/A 2027-11-15 |
ACCELERON PHARMA INC | XLRN | Smith Karen L. Director |
8,925 | $0 | 19,457 (Direct) |
View |
| 2021-04-05 Exercise |
2021-04-05 8:17 pm |
N/A N/A |
ACCELERON PHARMA INC | XLRN | Smith Karen L. Director |
1,875 | $41.64 | 19,457 (Direct) |
View |
| 2021-04-05 Exercise |
2021-04-05 8:17 pm |
N/A N/A |
ACCELERON PHARMA INC | XLRN | Smith Karen L. Director |
2,050 | $52.99 | 19,457 (Direct) |
View |
| 2021-04-01 Exercise |
2021-04-02 6:00 pm |
N/A N/A |
ACCELERON PHARMA INC | XLRN | Smith Karen L. Director |
5,000 | $35.34 | 31,321 (Direct) |
View |
| 2021-04-01 Exercise |
2021-04-02 6:00 pm |
N/A 2027-11-15 |
ACCELERON PHARMA INC | XLRN | Smith Karen L. Director |
8,925 | $0 | 31,321 (Direct) |
View |
| 2021-04-01 Exercise |
2021-04-02 6:00 pm |
N/A N/A |
ACCELERON PHARMA INC | XLRN | Smith Karen L. Director |
1,875 | $41.64 | 31,321 (Direct) |
View |
| 2021-04-01 Exercise |
2021-04-02 6:00 pm |
N/A N/A |
ACCELERON PHARMA INC | XLRN | Smith Karen L. Director |
2,050 | $52.99 | 31,321 (Direct) |
View |
| 2021-02-25 Option Award |
2021-03-01 9:05 pm |
N/A 2031-02-24 |
SANGAMO THERAPEUTICS INC | SGMO | Smith Karen L. Director |
24,600 | $0 | 42,100 (Direct) |
View |
| 2021-02-24 Option Award |
2021-02-26 5:15 pm |
N/A 2028-02-23 |
Emergent BioSolutions Inc. | EBS | Smith Karen L. EVP, Chief Medical Officer |
11,765 | $93.49 | 23,958 (Direct) |
View |
| 2021-02-24 Option Award |
2021-02-26 5:15 pm |
N/A N/A |
Emergent BioSolutions Inc. | EBS | Smith Karen L. EVP, Chief Medical Officer |
5,883 | $0 | 23,958 (Direct) |
View |
| 2021-01-29 Option Award |
2021-02-02 6:52 pm |
N/A 2031-01-29 |
ACCELERON PHARMA INC | XLRN | Smith Karen L. Director |
4,844 | $0 | 7,783 (Direct) |
View |
| 2020-06-11 Option Award |
2020-06-15 9:15 pm |
N/A N/A |
ANTARES PHARMA INC. | ATRS | Smith Karen L. Director |
30,220 | $2.73 | 112,439 (Direct) |
View |
| 2020-06-11 Option Award |
2020-06-15 9:15 pm |
N/A 2030-06-11 |
ANTARES PHARMA INC. | ATRS | Smith Karen L. Director |
58,246 | $0 | 112,439 (Direct) |
View |
| 2020-05-18 Option Award(A) |
2020-06-03 4:30 pm |
N/A 2030-05-17 |
SANGAMO THERAPEUTICS INC | SGMO | Smith Karen L. Director |
30,000 | $0 | 37,500 (Direct) |
View |
Ownership |
2020-05-28 7:35 pm |
N/A N/A |
Emergent BioSolutions Inc. | EBS | Smith Karen L. EVP, Chief Medical Officer |
0 | $0 | 18,929 (Direct) |
View |
| 2020-05-18 Option Award |
2020-05-20 5:21 pm |
N/A 2030-05-17 |
SANGAMO THERAPEUTICS INC | SGMO | Smith Karen L. Director |
17,500 | $0 | 25,000 (Direct) |
View |